Questions remain regarding patients with aortic stenosis and severe pulmonary hypertension: Reply  by Malouf, Joseph F et al.
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REPLY
We appreciate the interest of Dr. Rahimtoola in our study of
pulmonary hypertension in patients with aortic stenosis (1), and we
appreciate his comments underscoring the importance of the data.
Unfortunately, it was not possible to present all the data we
collected as space is limited by the Journal. Below are the responses
to the specific queries made:
1. Left ventricular ejection fraction was derived by two-
dimensional echocardiography using visual estimate in all pa-
tients and combining it to M-mode measurements in 23
patients (49%). This approach has been proven in previous
studies to be highly predictive of outcome, at least as well as
angiography (2).
2. The mean  SD (range) Doppler-derived calculations of the
pulmonary artery systolic pressure (PASP) assuming a mean
right atrial pressure of 10 mm Hg were:
79.5  8.0 mm Hg (74–106) for the entire group
82.0  11.6 mm Hg (74–106) for the No-AVR (aortic
value replacement) group
78.8  6.8 mm Hg (74–102) for the AVR group
These data confirm, irrespective of the estimated right atrial
pressure, that the pulmonary hypertension in our study population
was indeed severe.
3. With regard to coronary disease, 34 patients (72%) underwent
selective coronary angiography—AVR group, 32 patients
(86%); No-AVR group, 2 patients (20%). These rates are well
expected, as the small but definite risk of coronary angiography
is not warranted in patients who either refuse surgery or are not
considered candidates for surgery.
A total of 19 patients had initially unprotected obstructive
coronary artery disease—17 among the AVR-group patients, all of
whom underwent coronary artery bypass graft surgery (CABG).
The remaining 15 patients (all in the AVR group) had either
normal or minimally diseased coronary arteries (12 patients) or
patent grafts from prior CABG (3 patients). The five-year survival
rate of AVR patients who underwent CABG (58%, SE 0.16) was
not significantly different (p  0.87) from that of AVR patients
without obstructive coronary disease on angiography, including
those with previous bypass and patent grafts (48%, SE 0.18).
Moreover, there was no significant difference in the severity of
pulmonary hypertension between these two AVR subgroups
(PASP 78.4  4.8 mm Hg [74–87] for isolated AVR patients vs.
79.6  8.7 mm Hg (74–102) for AVR patients who needed
CABG; p  0.9). This suggests that the poor outcome in this
subset of patients is indeed the result of pulmonary hypertension
rather than that of coronary disease.
4. The five-year survival (mean  SE) for AVR patients, includ-
ing operative mortality, was 48  12%; the p value in compar-
ison to expected survival was 0.0001. Indeed, despite treat-
ment, this group is at high risk, although less than historical
controls with similar levels of pulmonary hypertension but no
aortic stenosis (AS) (3). Hence, an important conclusion of our
study is that it is essential that patients be operated on before
they reach such a considerable level of pulmonary hypertension.
Nevertheless, as operative results continuously improve, the
postoperative survival excluding operative mortality, in our
mind, is also important and supports hope of a better outcome
for patients with AS and severe pulmonary hypertension who
otherwise are at very high risk.
We appreciate the interest of Dr. Rahimtoola, which allows
underscoring further the importance of detecting pulmonary hy-
pertension in patients with aortic stenosis.
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Coronary Atherosclerosis
and Body Iron Stores
We read with great interest the study by Gaenzer et al. (1) in a
recent issue of the Journal. The investigators studied associations
between iron status and early functional and structural vascular
abnormalities in patients with hereditary hemochromatosis and
found that impaired endothelial function and increased intima-
media thickness (IMT) may be associated with iron overload, with
subsequent induction of oxidative stress. Gaenzer and colleagues
suggested that iron-depletion therapy, which normalizes endothe-
lial function, may reduce the increased risk of cardiovascular
events.
A possible association between body iron status and the risk of
coronary heart disease was first supported by findings from a
Finnish study relating increased levels of both serum ferritin and
dietary iron to an increased risk of myocardial infarction in men
(2). It is believed that inflammation and oxidation are important
mechanisms involved in the complex pathological process of
atherogenesis (3). Free radical production is catalyzed and accel-
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